Latest Breaking News On - With no reported serious adverse - Page 1 : comparemela.com

/PRNewswire/ Lannett Company, Inc. (NYSE: LCI) today provided an update on its ongoing pivotal clinical trial of biosimilar insulin glargine, a product the.

Sanofi lantusRobert jaffeCompany formLannett companyPrnewswire lannett company incLannett company incRobert jaffe coApproximately halfPlanned numberSubjects have receivedFirst doseWith no reported serious adverseTim crewBiologics license applicationMedical pharmaceuticalsHealth care amp hospitals